Bokf Na Increases Holdings in Abbott Laboratories $ABT

Bokf Na grew its holdings in shares of Abbott Laboratories (NYSE:ABT) by 4.8% in the 4th quarter, HoldingsChannel reports. The firm owned 147,016 shares of the healthcare product maker’s stock after acquiring an additional 6,708 shares during the quarter. Bokf Na’s holdings in Abbott Laboratories were worth $18,420,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently made changes to their positions in ABT. Harbor Capital Advisors Inc. purchased a new stake in shares of Abbott Laboratories during the 4th quarter valued at $27,000. Cloud Capital Management LLC purchased a new stake in shares of Abbott Laboratories during the 3rd quarter valued at $29,000. Guerra Advisors Inc purchased a new stake in shares of Abbott Laboratories during the 3rd quarter valued at $31,000. Bridge Generations Wealth Management LLC purchased a new stake in Abbott Laboratories in the 3rd quarter worth about $33,000. Finally, Copia Wealth Management purchased a new stake in Abbott Laboratories in the 3rd quarter worth about $38,000. 75.18% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on ABT. Jefferies Financial Group decreased their price objective on Abbott Laboratories from $145.00 to $135.00 and set a “buy” rating for the company in a report on Friday, April 17th. Citigroup decreased their price objective on Abbott Laboratories from $136.00 to $108.00 and set a “buy” rating for the company in a report on Friday, April 17th. BTIG Research reissued a “buy” rating and issued a $131.00 price objective on shares of Abbott Laboratories in a report on Monday, April 27th. Oppenheimer decreased their price objective on Abbott Laboratories from $132.00 to $115.00 and set an “outperform” rating for the company in a report on Friday, April 17th. Finally, Bank of America decreased their price objective on Abbott Laboratories from $150.00 to $120.00 and set a “buy” rating for the company in a report on Friday, April 17th. Two investment analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and five have assigned a Hold rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $119.43.

Abbott Laboratories Stock Down 0.4%

Shares of NYSE ABT opened at $87.18 on Wednesday. Abbott Laboratories has a 52 week low of $86.16 and a 52 week high of $139.06. The business has a 50-day simple moving average of $103.83 and a two-hundred day simple moving average of $115.68. The company has a quick ratio of 1.01, a current ratio of 1.39 and a debt-to-equity ratio of 0.56. The company has a market cap of $151.84 billion, a P/E ratio of 24.42, a P/E/G ratio of 1.46 and a beta of 0.65.

Abbott Laboratories (NYSE:ABT) last issued its earnings results on Thursday, April 16th. The healthcare product maker reported $1.15 EPS for the quarter, topping the consensus estimate of $1.14 by $0.01. Abbott Laboratories had a return on equity of 17.62% and a net margin of 13.90%.The business had revenue of $11.16 billion during the quarter, compared to the consensus estimate of $10.99 billion. During the same quarter last year, the company earned $1.09 EPS. The firm’s revenue was up 7.8% compared to the same quarter last year. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. Research analysts anticipate that Abbott Laboratories will post 5.48 earnings per share for the current fiscal year.

Abbott Laboratories Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, May 15th. Shareholders of record on Wednesday, April 15th will be paid a $0.63 dividend. The ex-dividend date is Wednesday, April 15th. This represents a $2.52 annualized dividend and a yield of 2.9%. Abbott Laboratories’s dividend payout ratio (DPR) is currently 70.59%.

Insiders Place Their Bets

In other Abbott Laboratories news, Director Daniel J. Starks purchased 10,000 shares of the company’s stock in a transaction dated Monday, April 27th. The stock was purchased at an average price of $92.65 per share, for a total transaction of $926,500.00. Following the transaction, the director owned 6,751,103 shares in the company, valued at $625,489,692.95. The trade was a 0.15% increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, SVP Eric Shroff sold 709 shares of Abbott Laboratories stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $115.58, for a total value of $81,946.22. Following the sale, the senior vice president owned 39,164 shares of the company’s stock, valued at approximately $4,526,575.12. This trade represents a 1.78% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 3,055 shares of company stock worth $353,097 over the last quarter. Insiders own 0.46% of the company’s stock.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.